Literature DB >> 30537383

Molecular Scaffolds as Double-Targeting Agents For the Diagnosis and Treatment of Neuroblastoma.

Gonzalo Villaverde1,2,3, Arantzazu Alfranca4,5, África Gonzalez-Murillo5,6, Gustavo J Melen5,6, Rafael R Castillo1,2,3, Manuel Ramírez5,6, Alejandro Baeza1,2,3,7, María Vallet-Regí1,2,3.   

Abstract

The selective delivery of therapeutic and imaging agents to tumoral cells has been postulated as one of the most important challenges in the nanomedicine field. Meta-iodobenzilguanidine (MIBG) is widely used for the diagnosis of neuroblastoma (NB) due to its strong affinity for the norepinephrine transporter (NET), usually overexpressed on the membrane of malignant cells. Herein, a family of novel Y-shaped scaffolds has been synthesized, which have structural analogues of MIBG covalently attached at each end of the Y-structure. The cellular uptake capacity of these double-targeting ligands has been evaluated in vitro and in vivo, yielding one specific Y-shaped structure that is able to be engulfed by the malignant cells, and accumulates in the tumoral tissue, at significantly higher levels than the structure containing only one single targeting agent. This Y-shaped ligand can provide a powerful tool for the current treatment and diagnosis of this disease.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  meta-iodobenzylguanidine; molecular scaffold; nanomedicine; neuroblastoma; targeting

Mesh:

Substances:

Year:  2019        PMID: 30537383      PMCID: PMC6667334          DOI: 10.1002/anie.201811691

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  17 in total

1.  Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.

Authors:  Huan Meng; Monty Liong; Tian Xia; Zongxi Li; Zhaoxia Ji; Jeffrey I Zink; Andre E Nel
Journal:  ACS Nano       Date:  2010-08-24       Impact factor: 15.881

2.  Synthesis and characterization of fluorescent ligands for the norepinephrine transporter: potential neuroblastoma imaging agents.

Authors:  D Hadrich; F Berthold; E Steckhan; H Bönisch
Journal:  J Med Chem       Date:  1999-08-12       Impact factor: 7.446

3.  Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues.

Authors:  G Vaidyanathan; S Shankar; D J Affleck; P C Welsh; S K Slade; M R Zalutsky
Journal:  Bioconjug Chem       Date:  2001 Sep-Oct       Impact factor: 4.774

4.  Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues.

Authors:  G Vaidyanathan; S Shankar; M R Zalutsky
Journal:  Bioconjug Chem       Date:  2001 Sep-Oct       Impact factor: 4.774

Review 5.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

6.  Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.

Authors:  Sean Carlin; Rob J Mairs; Anthony G McCluskey; Deborah A Tweddle; Alan Sprigg; Christine Estlin; Julian Board; Rani E George; Caroline Ellershaw; Andrew D J Pearson; John Lunec; Paolo G Montaldo; Mirco Ponzoni; Berthe L van Eck-Smit; Cees A Hoefnagel; Marieke D van den Brug; Godelieve A M Tytgat; Huib N Caron
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

7.  A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.

Authors:  Ganesan Vaidyanathan; Philip C Welsh; Katia C Vitorello; Stacey Snyder; Henry S Friedman; Michael R Zalutsky
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-16       Impact factor: 9.236

8.  Specificity and mobility of biomacromolecular, multivalent constructs for cellular targeting.

Authors:  Elena V Rosca; Jill M Stukel; Robert J Gillies; Josef Vagner; Michael R Caplan
Journal:  Biomacromolecules       Date:  2007-11-27       Impact factor: 6.988

9.  Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90.

Authors:  Byoung Heon Kang; Janet Plescia; Ho Young Song; Massimiliano Meli; Giorgio Colombo; Kristin Beebe; Bradley Scroggins; Len Neckers; Dario C Altieri
Journal:  J Clin Invest       Date:  2009-02-23       Impact factor: 14.808

10.  Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.

Authors:  Ganesan Vaidyanathan; Sriram Shankar; Donna J Affleck; Kevin Alston; Joseph Norman; Philip Welsh; Holly LeGrand; Michael R Zalutsky
Journal:  Bioorg Med Chem       Date:  2004-04-01       Impact factor: 3.641

View more
  5 in total

Review 1.  Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?

Authors:  María Vallet-Regí; Ferdi Schüth; Daniel Lozano; Montserrat Colilla; Miguel Manzano
Journal:  Chem Soc Rev       Date:  2022-07-04       Impact factor: 60.615

Review 2.  Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.

Authors:  Rafael R Castillo; Daniel Lozano; Blanca González; Miguel Manzano; Isabel Izquierdo-Barba; María Vallet-Regí
Journal:  Expert Opin Drug Deliv       Date:  2019-04-22       Impact factor: 6.648

Review 3.  Mesoporous Silica Nanoparticles for Targeting Subcellular Organelles.

Authors:  Miguel Gisbert-Garzarán; Daniel Lozano; María Vallet-Regí
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

Review 4.  Influence of the Surface Functionalization on the Fate and Performance of Mesoporous Silica Nanoparticles.

Authors:  Miguel Gisbert-Garzarán; María Vallet-Regí
Journal:  Nanomaterials (Basel)       Date:  2020-05-09       Impact factor: 5.076

Review 5.  Nanoantibiotics Based in Mesoporous Silica Nanoparticles: New Formulations for Bacterial Infection Treatment.

Authors:  Elena Álvarez; Blanca González; Daniel Lozano; Antonio L Doadrio; Montserrat Colilla; Isabel Izquierdo-Barba
Journal:  Pharmaceutics       Date:  2021-11-29       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.